{"success":true,"data":{"pressRelease":{"id":"43519","rtpr_id":"nGNX8CHdly","ticker":"ONCY","exchange":"NASDAQ","all_tickers":["ONCY"],"title":"Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors","author":"Globe Newswire","published_at":"2026-05-22T13:00:00.499Z","article_body":"SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech(®) Inc.\n(Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage\ncompany developing pelareorep, today announced translational data from the\nGOBLET and AWARE-1 trials will be presented at the 2026 American Society of\nClinical Oncology (“ASCO”) Annual Meeting at McCormick Place, Chicago,\nIllinois, from May 29-June 2, 2026. Pelareorep is an investigational,\nsystemically active immunotherapy that promotes potentially protective immune\nresponses, including the upregulation of key inflammatory cytokines resulting\nin the formation of tertiary lymphoid structures and the expansion of\ntumor-infiltrating lymphocytes.\n\n“These findings demonstrate that pelareorep works by expanding preexisting\ntumor-reactive immune cells rather than introducing new antigens,” said Dr.\nRichard Vile, Ph.D., Professor of Immunology at the Mayo Clinic and Oncolytics\nScientific Advisory Board Member. “This further underscores Oncolytics’\ncontinued commitment to define the mechanisms by which pelareorep engages the\nimmune system and illustrates the progress being made in developing a\ndifferentiated immunotherapy to improve treatment options for\ndifficult-to-treat cancers.”\n\n“KRAS-mutant tumors remain among the most challenging to treat with\nimmunotherapy,” said Jared Kelly, Chief Executive Officer of Oncolytics.\n“These data reflect important progress in bridging translational and\nclinical data and help us better understand how immune responses are activated\nby pelareorep. When we can point to translational and mechanistic data as the\nreason for clinical efficacy, it gives us confidence that our development\nplans are more likely to succeed.”\n\nAbstract: Influence of pelareorep on mutant KRAS-specific blood TIL clonal\nexpansion.\nAuthor: Richard Trauger, PhD\nDate: May 30, 2026, 1:30-4:30 p.m. Central Time\nAbstract Number: 2664\nPoster Board Number: 454\n\nTranslational analyses from the Phase 1/2 GOBLET study in advanced pancreatic\ncancer and the AWARE-1 window-of-opportunity study in early-stage breast\ncancer illustrate a multi‑step immune activation process following treatment\nwith pelareorep. Results demonstrate that pelareorep induces an antiviral\nimmune response within the tumor via double-stranded RNA signaling, leading to\nexpansion of virus‑specific T cells and subsequent activation of\ntumor‑specific T cells associated with tumor regression.\n\nIn pancreatic cancer, serial blood analyses demonstrated expansion of\nanti‑viral T cells by ELISPOT and clonal expansion of tumor‑specific T\ncells after one cycle of therapy. Notably, the expansion of pre‑existing\ntumor‑infiltrating lymphocyte (“TIL”) clones in blood correlated with\nreductions in tumor volume in pancreatic cancer. T‑cell receptor sequencing\nwith antigen specificity assessment confirmed expansion of mutant\nKRAS-specific T‑cell clones, supporting a model in which pelareorep engages\nboth innate and adaptive immunity and may help drive tumor‑directed immune\nresponses in difficult‑to‑treat, KRAS‑driven disease.\n\nIn serial breast tumor biopsies, gene expression profiling demonstrated\nsignificant increases in antiviral and immune gene expression, consistent with\nactivation of toll‑like receptor 3 (TLR3), alongside induction of CXCL13, a\nchemokine linked to the formation of tertiary lymphoid structures (TLS). TLS\nformation in the tumor microenvironment was further supported by imaging mass\ncytometry following treatment. Across studies, evidence of the expansion of\nTILs was observed in the tumor and the blood.\n\nA copy of the ASCO presentation will be available on the Media page\n(https://www.globenewswire.com/Tracker?data=I8bOyUFE0MMegIcc6rX9Es65-Ncqdo-Lvdwh70-4XkH_u1GUKNdkIjOUzukFOZ_i3lkur5cIu2H3DeitVXAQRIpiut_VXAumPbBmiQrXPpY=)\nof the Oncolytics’ website following the conclusion of the meeting.\n\nAbout GOBLET \nThe GOBLET (Gastrointestinal tumOrs exploring the treatment comBinations with\nthe oncolytic reovirus peLarEorep and anTi-PD-L1) study is a phase 1/2\nmultiple indication study in advanced or metastatic gastrointestinal tumors.\nThe study is being conducted at 17 centers in Germany and is being managed by\nAIO-Studien-gGmbH. The co-primary endpoints of the study are objective\nresponse rate and/or disease control rate and safety. Key secondary and\nexploratory endpoints include additional efficacy assessments and evaluation\nof potential biomarkers. The study comprises five treatment groups:\n1. Pelareorep in combination with atezolizumab (Tecentriq(®)), gemcitabine,\nand nab-paclitaxel in 1(st) line advanced/metastatic pancreatic cancer\npatients;\n2. Pelareorep in combination with atezolizumab in 1(st) line MSI\n(microsatellite instability)-high metastatic colorectal cancer patients;\n3. Pelareorep in combination with atezolizumab and TAS-102 in 3(rd) line\nmetastatic colorectal cancer patients\n4. Pelareorep in combination with atezolizumab in 2(nd) line advanced and\nunresectable anal cancer patients; and\n5. Pelareorep in combination with mFOLFIRINOX with and without atezolizumab in\nnewly diagnosed metastatic PDAC patients.\nAbout AIO \nAIO-Studien-gGmbH (“AIO”) emerged from the study center of the medical\noncology working group\n(https://www.globenewswire.com/Tracker?data=ktg2ZvQUjEvu90BoAvA9kAMiiQKsndEkVvxo9AKJuIKp0McGp8py4lVfZVHENNabq6NsvKXDsZYJBVI1eztxBeAPhgL2NJqOh0jCn1dh7olSRBSqLa_QUCBIbqmLrgB1LIOGr18nfcctm_Dhk1P7Gm9WrmRf-OIXxayRkJzWKpLmWaIz7opIZ1e5wag8HvIZ6QY2G4PW5Xv--QseivdLqBbDoWjwTQkBIqI3YLK5rwFnsHrim0e63oNa_oYBEr0PW3t-k0GHoHCP4M0N3hNIcFyRmjLY5q19SKQ_I3nkSMCrveiLZLPDLVmBSghhnIs-) within\nthe German Cancer Society (DKG). AIO operates with a non-profit purpose of\npromoting science and research with a focus on medical oncology. Since its\nfoundation, AIO has become a successful sponsor and study management company\nand has established itself both nationally and internationally.\n\nAbout AWARE-1 \nAWARE-1 was an open-label window-of-opportunity study in early-stage breast\ncancer. The study combined pelareorep, without or with atezolizumab, and\nstandard of care therapy according to breast cancer subtype. Tumor tissue was\ncollected from patients as part of their initial breast cancer diagnosis,\nagain on day three following initial treatment, and finally at three weeks\nfollowing treatment, on the day their tumor is surgically resected. Key\nobjectives of the study were to confirm that pelareorep is acting as a novel\nimmunotherapy, to evaluate potential synergy between pelareorep and checkpoint\nblockade, and to collect biomarker data. The primary endpoint of the\ntranslational study was overall CelTIL score (a measurement of cellularity and\ntumor-infiltrating lymphocytes that is associated with favorable clinical\noutcomes). Secondary endpoints for the study included safety and tumor and\nblood-based biomarkers. The combination of pelareorep, letrozole, and\natezolizumab resulted in 60% of patients experiencing 30% or greater increases\nin their CelTIL score.\n\nAbout Oncolytics Biotech Inc.\nOncolytics is a clinical-stage biotechnology company developing pelareorep, an\ninvestigational intravenously delivered double-stranded RNA immunotherapeutic\nagent. Pelareorep has demonstrated encouraging results in multiple first-line\npancreatic cancer studies, two randomized Phase 2 studies in metastatic breast\ncancer, and early-phase studies in anal and colorectal cancer. It is designed\nto induce anti-cancer immune responses by converting immunologically\n“cold” tumors “hot” through the activation of innate and adaptive\nimmune responses.\n\nThe Company is advancing pelareorep in combination with chemotherapy and/or\ncheckpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep\nhas received Fast Track designation from the FDA for colorectal and pancreatic\ncancer. Oncolytics is actively pursuing strategic partnerships to accelerate\ndevelopment and maximize commercial impact. For more about Oncolytics, please\nvisit: www.oncolyticsbiotech.com or follow the Company on social media on\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=VQuiFYkNliENQdrzhA7EcNXVjM9dJTyIoJHmL91VmgH3XDXCJ5KCGJ5KfZeegUB3yBhmjv7PkSkVP6IngC9Ow_HrWo5Ni9zQCoRZ-dbY8N9zJbX0io-h82ZoV_P6ZQ5a)\nand on X @oncolytics\n(https://www.globenewswire.com/Tracker?data=G_6kfiyho3pCv8WeAOYoIyeXybnzZhhC-GroSnUP-U6SeG6PuAXA_oiEwwhM1orr2o5qlHKxQmYDZUoN4dIO1w==).\n\nTecentriq(®) (atezolizumab) is a registered trademark of Genentech, a member\nof the Roche Group.\n\nForward-looking statements\nThis press release contains forward-looking statements, within the meaning of\nSection 21E of the U.S. Securities Exchange Act of 1934, as amended, and\nforward-looking information under applicable Canadian securities laws (such\nforward-looking statements and forward-looking information are collectively\nreferred to herein as “forward-looking statements”). Forward-looking\nstatements contained in this press release include statements regarding\nbeliefs as to the potential, registration, mechanism of action and benefits of\npelareorep as a cancer therapeutic; the Company’s goals, strategies, and\nobjectives; expectations around the design, milestones, anticipated timelines\nand expected outcomes for current and future studies, its belief in the\nclinical promise of pelareorep in anal, colorectal, pancreatic and other\ngastrointestinal cancers; the Company’s goals and expectations for its\npotential registrational development path for pelareorep in multiple\ngastrointestinal cancers; and plans for future disclosure of clinical trial\nresults. In any forward-looking statement in which Oncolytics expresses an\nexpectation or belief as to future results, such expectations or beliefs are\nexpressed in good faith and are believed to have a reasonable basis, but there\ncan be no assurance that the statement or expectation or belief will be\nachieved. These statements involve known and unknown risks and uncertainties\nthat may cause actual results to differ materially from those anticipated.\nThese risks include, but are not limited to, regulatory outcomes, trial\nexecution, financial resources, access to capital markets, and market\ndynamics. Please refer to Oncolytics’ public filings with securities\nregulators in the United States and Canada for more information. The Company\nassumes no obligation to update forward-looking statements, except as required\nby law.\n\nCompany Contact \nJon Patton\nDirector of IR & Communication\njpatton@oncolytics.ca\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f0121259-b2be-4290-90a3-0d2c3b243aed)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8CHdly","title":"Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors","author":"Globe Newswire","ticker":"ONCY","created":"2026-05-22T13:00:00.499Z","tickers":["ONCY"],"exchange":"NASDAQ","article_body":"SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech(®) Inc.\n(Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage\ncompany developing pelareorep, today announced translational data from the\nGOBLET and AWARE-1 trials will be presented at the 2026 American Society of\nClinical Oncology (“ASCO”) Annual Meeting at McCormick Place, Chicago,\nIllinois, from May 29-June 2, 2026. Pelareorep is an investigational,\nsystemically active immunotherapy that promotes potentially protective immune\nresponses, including the upregulation of key inflammatory cytokines resulting\nin the formation of tertiary lymphoid structures and the expansion of\ntumor-infiltrating lymphocytes.\n\n“These findings demonstrate that pelareorep works by expanding preexisting\ntumor-reactive immune cells rather than introducing new antigens,” said Dr.\nRichard Vile, Ph.D., Professor of Immunology at the Mayo Clinic and Oncolytics\nScientific Advisory Board Member. “This further underscores Oncolytics’\ncontinued commitment to define the mechanisms by which pelareorep engages the\nimmune system and illustrates the progress being made in developing a\ndifferentiated immunotherapy to improve treatment options for\ndifficult-to-treat cancers.”\n\n“KRAS-mutant tumors remain among the most challenging to treat with\nimmunotherapy,” said Jared Kelly, Chief Executive Officer of Oncolytics.\n“These data reflect important progress in bridging translational and\nclinical data and help us better understand how immune responses are activated\nby pelareorep. When we can point to translational and mechanistic data as the\nreason for clinical efficacy, it gives us confidence that our development\nplans are more likely to succeed.”\n\nAbstract: Influence of pelareorep on mutant KRAS-specific blood TIL clonal\nexpansion.\nAuthor: Richard Trauger, PhD\nDate: May 30, 2026, 1:30-4:30 p.m. Central Time\nAbstract Number: 2664\nPoster Board Number: 454\n\nTranslational analyses from the Phase 1/2 GOBLET study in advanced pancreatic\ncancer and the AWARE-1 window-of-opportunity study in early-stage breast\ncancer illustrate a multi‑step immune activation process following treatment\nwith pelareorep. Results demonstrate that pelareorep induces an antiviral\nimmune response within the tumor via double-stranded RNA signaling, leading to\nexpansion of virus‑specific T cells and subsequent activation of\ntumor‑specific T cells associated with tumor regression.\n\nIn pancreatic cancer, serial blood analyses demonstrated expansion of\nanti‑viral T cells by ELISPOT and clonal expansion of tumor‑specific T\ncells after one cycle of therapy. Notably, the expansion of pre‑existing\ntumor‑infiltrating lymphocyte (“TIL”) clones in blood correlated with\nreductions in tumor volume in pancreatic cancer. T‑cell receptor sequencing\nwith antigen specificity assessment confirmed expansion of mutant\nKRAS-specific T‑cell clones, supporting a model in which pelareorep engages\nboth innate and adaptive immunity and may help drive tumor‑directed immune\nresponses in difficult‑to‑treat, KRAS‑driven disease.\n\nIn serial breast tumor biopsies, gene expression profiling demonstrated\nsignificant increases in antiviral and immune gene expression, consistent with\nactivation of toll‑like receptor 3 (TLR3), alongside induction of CXCL13, a\nchemokine linked to the formation of tertiary lymphoid structures (TLS). TLS\nformation in the tumor microenvironment was further supported by imaging mass\ncytometry following treatment. Across studies, evidence of the expansion of\nTILs was observed in the tumor and the blood.\n\nA copy of the ASCO presentation will be available on the Media page\n(https://www.globenewswire.com/Tracker?data=I8bOyUFE0MMegIcc6rX9Es65-Ncqdo-Lvdwh70-4XkH_u1GUKNdkIjOUzukFOZ_i3lkur5cIu2H3DeitVXAQRIpiut_VXAumPbBmiQrXPpY=)\nof the Oncolytics’ website following the conclusion of the meeting.\n\nAbout GOBLET \nThe GOBLET (Gastrointestinal tumOrs exploring the treatment comBinations with\nthe oncolytic reovirus peLarEorep and anTi-PD-L1) study is a phase 1/2\nmultiple indication study in advanced or metastatic gastrointestinal tumors.\nThe study is being conducted at 17 centers in Germany and is being managed by\nAIO-Studien-gGmbH. The co-primary endpoints of the study are objective\nresponse rate and/or disease control rate and safety. Key secondary and\nexploratory endpoints include additional efficacy assessments and evaluation\nof potential biomarkers. The study comprises five treatment groups:\n1. Pelareorep in combination with atezolizumab (Tecentriq(®)), gemcitabine,\nand nab-paclitaxel in 1(st) line advanced/metastatic pancreatic cancer\npatients;\n2. Pelareorep in combination with atezolizumab in 1(st) line MSI\n(microsatellite instability)-high metastatic colorectal cancer patients;\n3. Pelareorep in combination with atezolizumab and TAS-102 in 3(rd) line\nmetastatic colorectal cancer patients\n4. Pelareorep in combination with atezolizumab in 2(nd) line advanced and\nunresectable anal cancer patients; and\n5. Pelareorep in combination with mFOLFIRINOX with and without atezolizumab in\nnewly diagnosed metastatic PDAC patients.\nAbout AIO \nAIO-Studien-gGmbH (“AIO”) emerged from the study center of the medical\noncology working group\n(https://www.globenewswire.com/Tracker?data=ktg2ZvQUjEvu90BoAvA9kAMiiQKsndEkVvxo9AKJuIKp0McGp8py4lVfZVHENNabq6NsvKXDsZYJBVI1eztxBeAPhgL2NJqOh0jCn1dh7olSRBSqLa_QUCBIbqmLrgB1LIOGr18nfcctm_Dhk1P7Gm9WrmRf-OIXxayRkJzWKpLmWaIz7opIZ1e5wag8HvIZ6QY2G4PW5Xv--QseivdLqBbDoWjwTQkBIqI3YLK5rwFnsHrim0e63oNa_oYBEr0PW3t-k0GHoHCP4M0N3hNIcFyRmjLY5q19SKQ_I3nkSMCrveiLZLPDLVmBSghhnIs-) within\nthe German Cancer Society (DKG). AIO operates with a non-profit purpose of\npromoting science and research with a focus on medical oncology. Since its\nfoundation, AIO has become a successful sponsor and study management company\nand has established itself both nationally and internationally.\n\nAbout AWARE-1 \nAWARE-1 was an open-label window-of-opportunity study in early-stage breast\ncancer. The study combined pelareorep, without or with atezolizumab, and\nstandard of care therapy according to breast cancer subtype. Tumor tissue was\ncollected from patients as part of their initial breast cancer diagnosis,\nagain on day three following initial treatment, and finally at three weeks\nfollowing treatment, on the day their tumor is surgically resected. Key\nobjectives of the study were to confirm that pelareorep is acting as a novel\nimmunotherapy, to evaluate potential synergy between pelareorep and checkpoint\nblockade, and to collect biomarker data. The primary endpoint of the\ntranslational study was overall CelTIL score (a measurement of cellularity and\ntumor-infiltrating lymphocytes that is associated with favorable clinical\noutcomes). Secondary endpoints for the study included safety and tumor and\nblood-based biomarkers. The combination of pelareorep, letrozole, and\natezolizumab resulted in 60% of patients experiencing 30% or greater increases\nin their CelTIL score.\n\nAbout Oncolytics Biotech Inc.\nOncolytics is a clinical-stage biotechnology company developing pelareorep, an\ninvestigational intravenously delivered double-stranded RNA immunotherapeutic\nagent. Pelareorep has demonstrated encouraging results in multiple first-line\npancreatic cancer studies, two randomized Phase 2 studies in metastatic breast\ncancer, and early-phase studies in anal and colorectal cancer. It is designed\nto induce anti-cancer immune responses by converting immunologically\n“cold” tumors “hot” through the activation of innate and adaptive\nimmune responses.\n\nThe Company is advancing pelareorep in combination with chemotherapy and/or\ncheckpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep\nhas received Fast Track designation from the FDA for colorectal and pancreatic\ncancer. Oncolytics is actively pursuing strategic partnerships to accelerate\ndevelopment and maximize commercial impact. For more about Oncolytics, please\nvisit: www.oncolyticsbiotech.com or follow the Company on social media on\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=VQuiFYkNliENQdrzhA7EcNXVjM9dJTyIoJHmL91VmgH3XDXCJ5KCGJ5KfZeegUB3yBhmjv7PkSkVP6IngC9Ow_HrWo5Ni9zQCoRZ-dbY8N9zJbX0io-h82ZoV_P6ZQ5a)\nand on X @oncolytics\n(https://www.globenewswire.com/Tracker?data=G_6kfiyho3pCv8WeAOYoIyeXybnzZhhC-GroSnUP-U6SeG6PuAXA_oiEwwhM1orr2o5qlHKxQmYDZUoN4dIO1w==).\n\nTecentriq(®) (atezolizumab) is a registered trademark of Genentech, a member\nof the Roche Group.\n\nForward-looking statements\nThis press release contains forward-looking statements, within the meaning of\nSection 21E of the U.S. Securities Exchange Act of 1934, as amended, and\nforward-looking information under applicable Canadian securities laws (such\nforward-looking statements and forward-looking information are collectively\nreferred to herein as “forward-looking statements”). Forward-looking\nstatements contained in this press release include statements regarding\nbeliefs as to the potential, registration, mechanism of action and benefits of\npelareorep as a cancer therapeutic; the Company’s goals, strategies, and\nobjectives; expectations around the design, milestones, anticipated timelines\nand expected outcomes for current and future studies, its belief in the\nclinical promise of pelareorep in anal, colorectal, pancreatic and other\ngastrointestinal cancers; the Company’s goals and expectations for its\npotential registrational development path for pelareorep in multiple\ngastrointestinal cancers; and plans for future disclosure of clinical trial\nresults. In any forward-looking statement in which Oncolytics expresses an\nexpectation or belief as to future results, such expectations or beliefs are\nexpressed in good faith and are believed to have a reasonable basis, but there\ncan be no assurance that the statement or expectation or belief will be\nachieved. These statements involve known and unknown risks and uncertainties\nthat may cause actual results to differ materially from those anticipated.\nThese risks include, but are not limited to, regulatory outcomes, trial\nexecution, financial resources, access to capital markets, and market\ndynamics. Please refer to Oncolytics’ public filings with securities\nregulators in the United States and Canada for more information. The Company\nassumes no obligation to update forward-looking statements, except as required\nby law.\n\nCompany Contact \nJon Patton\nDirector of IR & Communication\njpatton@oncolytics.ca\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f0121259-b2be-4290-90a3-0d2c3b243aed)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-22T13:00:00.542391868Z","server_sent_at_ms":1779454800542},"received_at":"2026-05-22T13:00:00.923Z","source_url":null},"analysis":{"id":"32958","press_release_id":"43519","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Oncolytics Biotech will present translational data from the GOBLET and AWARE-1 trials at the ASCO 2026 Annual Meeting, reinforcing pelareorep’s mechanism of action in gastrointestinal tumors.\n\nThe data demonstrates that pelareorep expands preexisting tumor-reactive immune cells, specifically mutant KRAS-specific T-cell clones, rather than introducing new antigens.\n\nIn the AWARE-1 breast cancer study, 60% of patients treated with pelareorep, letrozole, and atezolizumab saw a 30% or greater increase in their CelTIL score, a biomarker associated with favorable clinical outcomes.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Mechanistic validation at ASCO: Pelareorep shown to expand KRAS-specific T-cells, de-risking development in hard-to-treat GI cancers."},"keyFigures":{"drugName":"pelareorep","customDimensions":{"celtil_increase_rate":"60%","celtil_increase_threshold":"30%"}},"quotedText":"These data reflect important progress in bridging translational and clinical data and help us better understand how immune responses are activated by pelareorep.","namedEntities":{"people":[{"name":"Dr. Richard Vile","role":"Professor of Immunology at Mayo Clinic / Scientific Advisory Board Member"},{"name":"Jared Kelly","role":"CEO"},{"name":"Richard Trauger","role":"Author"},{"name":"Jon Patton","role":"Director of IR & Communication"}],"products":["pelareorep","Tecentriq","atezolizumab","gemcitabine","nab-paclitaxel","TAS-102","mFOLFIRINOX","letrozole"],"companies":[{"name":"Oncolytics Biotech Inc.","ticker":"ONCY"},{"name":"Mayo Clinic","relationship":"scientific partner"},{"name":"AIO-Studien-gGmbH","relationship":"study manager"},{"name":"German Cancer Society","relationship":"parent organization of AIO"},{"name":"Genentech","relationship":"trademark holder for Tecentriq"},{"name":"Roche Group","relationship":"parent of Genentech"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Presentation of translational/mechanistic data at a major conference (ASCO) supports the scientific rationale for pelareorep in difficult-to-treat KRAS-mutant tumors. While not a pivotal efficacy readout, it de-risks the development path and validates the mechanism of action, which is critical for a clinical-stage biotech."},"tickerRelevance":{"others":[],"primary":"ONCY"},"globalImportance":35,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"mid-tier (translational data, not pivotal)","sectorWeight":"high","householdBrandBoost":0,"retailFavoriteBoost":0}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Oncolytics Biotech will present translational data from the GOBLET and AWARE-1 trials at the ASCO 2026 Annual Meeting, reinforcing pelareorep’s mechanism of action in gastrointestinal tumors.\n\nThe data demonstrates that pelareorep expands preexisting tumor-reactive immune cells, specifically mutant KRAS-specific T-cell clones, rather than introducing new antigens.\n\nIn the AWARE-1 breast cancer study, 60% of patients treated with pelareorep, letrozole, and atezolizumab saw a 30% or greater increase in their CelTIL score, a biomarker associated with favorable clinical outcomes.","key_figures":{"drugName":"pelareorep","customDimensions":{"celtil_increase_rate":"60%","celtil_increase_threshold":"30%"}},"named_entities":{"people":[{"name":"Dr. Richard Vile","role":"Professor of Immunology at Mayo Clinic / Scientific Advisory Board Member"},{"name":"Jared Kelly","role":"CEO"},{"name":"Richard Trauger","role":"Author"},{"name":"Jon Patton","role":"Director of IR & Communication"}],"products":["pelareorep","Tecentriq","atezolizumab","gemcitabine","nab-paclitaxel","TAS-102","mFOLFIRINOX","letrozole"],"companies":[{"name":"Oncolytics Biotech Inc.","ticker":"ONCY"},{"name":"Mayo Clinic","relationship":"scientific partner"},{"name":"AIO-Studien-gGmbH","relationship":"study manager"},{"name":"German Cancer Society","relationship":"parent organization of AIO"},{"name":"Genentech","relationship":"trademark holder for Tecentriq"},{"name":"Roche Group","relationship":"parent of Genentech"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-22T13:01:11.763Z","global_importance":35,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap","eventGravity":"mid-tier (translational data, not pivotal)","sectorWeight":"high","householdBrandBoost":0,"retailFavoriteBoost":0}},"durationMs":23914,"modelName":"george-droid-qwen-72b"}}